| Size | Price | |
|---|---|---|
| 50mg | ||
| 100mg | ||
| Other Sizes |
| Targets |
Biotin-PEG-Thiol targets streptavidin or avidin proteins through its biotin moiety. The biotin-streptavidin interaction is one of the strongest non-covalent bonds known. Additionally, the thiol group targets maleimide groups or gold surfaces, forming a stable covalent thioether bond or gold-thiol bond, respectively. These properties make it a versatile reagent for linking biomolecules to surfaces or creating multi-functional probes.
|
|---|---|
| ln Vitro |
In vitro, Biotin-PEG-Thiol is used as a functionalized ligand in surface chemistry. For example, in Tris buffer (10 mM, pH 8.5), a poly(Tyr-CB) membrane-coated substrate is immersed in an aqueous solution of Biotin-PEG-Thiol (1 mM) for 24 hours at room temperature. This results in the immobilization of biotin groups onto the substrate, allowing subsequent high-affinity capture of streptavidin-conjugated proteins or nanoparticles.
|
| ln Vivo |
In vivo activity data for Biotin-PEG-Thiol (MW 2000) have not been reported. As an active polymer and research-use compound, it is designed for in vitro applications like surface functionalization and bioconjugation. It is not intended for in vivo administration, and no animal efficacy or pharmacokinetic studies have been conducted for this polymer.
|
| Enzyme Assay |
In a typical non-cellular binding or conjugation assay, the compound is used to immobilize biotin on a maleimide- or gold-coated surface. The substrate is immersed in an aqueous solution of Biotin-PEG-Thiol (1 mM) under mild alkaline conditions (e.g., 10 mM Tris buffer, pH 8.5) at room temperature for 24 hours. After rinsing with PBS, the biotin-functionalized substrate can be used to capture streptavidin-coated quantum dots or enzymes.
|
| Cell Assay |
In cellular applications, Biotin-PEG-Thiol can be used to label cell surface proteins. For instance, after being conjugated to a maleimide-activated targeting ligand (like a peptide or antibody), the complex is incubated with live cells. The biotin tag on the complex then allows for detection using fluorescently labeled streptavidin. The interaction can be quantified by flow cytometry or visualized by fluorescence microscopy after a 30-60 minute incubation at 4degC.
|
| Animal Protocol |
Detailed in vivo animal experimental protocols for Biotin-PEG-Thiol (MW 2000) are not described in the literature. The compound's application is strictly as a research tool for in vitro bioconjugation and surface chemistry. In vivo administration studies are not standard for this type of reagent, and no specific dosing or animal model data are available.
|
| ADME/Pharmacokinetics |
Dedicated pharmacokinetic (PK) studies for Biotin-PEG-Thiol (MW 2000) are not applicable. As a PEGylated polymer, it is highly soluble and the thiol group is reactive. Its role as a linker is to improve the PK properties of conjugated drugs. When conjugated to a therapeutic protein, the PEG chain increases the effective molecular weight, reducing kidney filtration, prolonging circulation half-life, and decreasing immunogenicity.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for Biotin-PEG-Thiol (MW 2000) are not reported in standard product literature. As a research-use polymer, standard safety assessments for acute toxicity, genotoxicity, and organ-specific toxicity are not typically described. For laboratory use, standard chemical safety precautions should be followed. Polyethylene glycols are generally considered low in toxicity.
|
| References |
[1]. Tania Patino, et al. Multifunctional gold nanorods for selective plasmonic photothermal therapy in pancreatic cancer cells using ultra-short pulse near-infrared laser irradiation. Nanoscale. 2015 Mar 12;7(12):5328-37.
|
| Additional Infomation |
Biotin-PEG-Thiol (MW 2000) is a heterobifunctional PEG derivative. The PEG chain has an average molecular weight of 2000 Da, and the compound is typically stored as a solid at -20degC. It is an active polymer that is used in the research of nanomaterials, surface functionalization, and the development of targeted drug delivery systems. The product is intended for research purposes only and is not for human therapy.
|
| Molecular Formula |
C14H25N3O3S2
|
|---|---|
| Molecular Weight |
2000(Average)
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
